Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denosumab biosimilar - Shanghai Biomabs Pharmaceutical

Next Previous
Drug Profile

Denosumab biosimilar - Shanghai Biomabs Pharmaceutical

Alternative Names: CMAB-807; CMAB-807X

Latest Information Update: 04 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Biomabs Pharmaceuticals
  • Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Osteoporosis

Most Recent Events

  • 01 Nov 2024 Shanghai Biomabs Pharmaceutical completes a phase III trial in Osteoporosis in China (SC) (NCT04591275)
  • 05 Jul 2024 Taizhou Mabtech Pharmaceutical Co completes a phase I trial in healthy volunteers in China (SC) (NCT06361355)
  • 09 Apr 2024 Taizhou Mabtech Pharmaceutical withdraws phase-I pharmacokinetic, pharmacodynamics and safety trial (In volunteers) in China (SC, injection) prior enrolment due to changes in the company's production plan (NCT05808673)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top